Anti‐VEGF therapy can alleviate the VEGF‐mediated suppression of T cells, normalize the tumor vasculature, enhance immune cell infiltration, and synergistically improve the efficacy of PD‐1/PD‐L1 inhibitors [92]. The gene discussed is VEGFA; the disease is neoplasm.